Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Azafaros Secures $150M Series B Funding to Advance Rare Disease Therapies

Azafaros, a Dutch biotech company, has successfully raised €132 million ($148 million) in a Series B financing round to further develop treatments for rare lysosomal storage disorders. The funding, led by Jeito Capital and Forbion Growth, will primarily support the advancement of the company's lead asset, nizubaglustat, into late-stage clinical trials.

NoahAI News5/14/2025

Galapagos Reverses Course on Split, Appoints New CEO to Lead Strategic Transformation

Galapagos NV, a Belgium-based biopharmaceutical company, has announced a significant shift in its corporate strategy, backtracking on previously announced plans to split into two separate entities. The company has also appointed industry veteran Henry Gosebruch as its new CEO, signaling a renewed focus on strategic dealmaking and business development.

NoahAI News5/14/2025

TIGIT Setback: iTeos and GSK Halt Development of Cancer Immunotherapy

In a significant blow to the field of cancer immunotherapy, iTeos Therapeutics and GlaxoSmithKline (GSK) have announced the termination of their collaboration on belrestotug, a promising TIGIT-blocking drug. This decision comes after disappointing results in a Phase 2 clinical trial, marking another setback for the TIGIT class of cancer treatments that have struggled to meet expectations.

NoahAI News5/14/2025

Roche Announces $550M Investment in Indianapolis CGM Manufacturing Hub

Roche, the Swiss pharmaceutical giant, has unveiled plans for a significant expansion of its Indianapolis diagnostics campus, with a $550 million investment aimed at transforming the site into a U.S. manufacturing and distribution hub for its wearable diabetes blood sugar sensors. This move comes as part of a larger $50 billion commitment to expand the company's U.S. footprint in research, development, and production by 2030.

NoahAI News5/14/2025

Roche's Perjeta-Based Regimen Shows Long-Term Survival Benefit in HER2-Positive Breast Cancer

Roche has unveiled compelling long-term survival data for its Perjeta-based regimen in early-stage HER2-positive breast cancer, reinforcing the treatment's position as a standard of care in the adjuvant setting. The Swiss pharmaceutical giant presented the results from its phase 3 APHINITY study at the 2025 European Society for Medical Oncology Breast Cancer Congress, demonstrating sustained benefits after a decade of follow-up.

NoahAI News5/14/2025

UnitedHealth Group CEO Andrew Witty Steps Down Amid Financial Challenges

In a surprising turn of events, UnitedHealth Group announced on Tuesday that CEO Andrew Witty is stepping down from his role, citing personal reasons. The healthcare giant also suspended its 2025 financial guidance, sending shockwaves through the industry and causing a significant drop in the company's stock price.

NoahAI News5/14/2025

Erasca Shifts Focus to Early-Stage RAS-Targeting Candidates, Seeks Partner for Advanced Asset

Erasca, a San Diego-based cancer-focused biotech company, has announced a strategic pivot in its drug development pipeline, opting to seek a partner for its most advanced asset while redirecting resources to two early-stage RAS-targeting candidates. This move aims to extend the company's cash runway and capitalize on the potential of its newer assets in the competitive oncology landscape.

NoahAI News5/14/2025

Atara Biotherapeutics Announces Further Layoffs Despite FDA Lifting Clinical Hold

Atara Biotherapeutics, a biopharma company focused on T-cell immunotherapies, has announced another round of layoffs affecting 30% of its remaining workforce. This decision comes just days after the U.S. Food and Drug Administration (FDA) lifted a clinical hold on the company's lead product, Ebvallo.

NoahAI News5/14/2025

Teal Health Receives FDA Approval for At-Home Cervical Cancer Screening Device

Teal Health has secured Food and Drug Administration (FDA) approval for its innovative at-home cervical cancer screening sample collection device, marking a significant advancement in women's health diagnostics. The company announced on Friday that its product, the Teal Wand, is the first FDA-approved device of its kind, offering patients a convenient and private alternative to traditional in-office screenings.

NoahAI News5/14/2025

Bluebird Bio's Buyout Saga: Bankruptcy Looms as Shareholders Hesitate

Bluebird bio, once a high-flying gene therapy pioneer, finds itself at a critical juncture as shareholders drag their feet on a proposed buyout, potentially pushing the company to the brink of bankruptcy. The Massachusetts-based biotech's struggle highlights the challenges facing innovative yet financially strained companies in the pharmaceutical sector.

NoahAI News5/14/2025

Novo Nordisk's Sogroya Shows Promise in Pediatric Growth Disorders

Novo Nordisk has unveiled promising results from its phase 3 REAL8 trial, demonstrating that its once-weekly human growth hormone analogue Sogroya is comparable to its daily predecessor, Norditropin, in treating multiple pediatric growth disorders. This development marks a significant step forward in the company's rare disease strategy and could potentially reshape treatment options for children with growth-related conditions.

NoahAI News5/14/2025

GSK Terminates $625M TIGIT Program as Clinical Data Falls Short of Expectations

GSK has announced the discontinuation of its anti-TIGIT antibody program, belrestotug, following disappointing clinical trial results. The decision, made in conjunction with development partner iTeos Therapeutics, comes after an assessment of progression-free survival data failed to meet expectations in multiple studies.

NoahAI News5/14/2025

«1...63 64 65...67 »